VANCOUVER, British Columbia (AP) _ Novelion Therapeutics Inc. (NVLN) on Tuesday reported a loss of $31.3 million in its second quarter.
On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of $1.67. Losses, adjusted for amortization costs and non-recurring costs, came to 59 cents per share.
The retinal disease treatment developer posted revenue of $31.9 million in the period.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NVLN at https://www.zacks.com/ap/NVLN